Minocycline Topical Foam to be Available in Pharmacies Starting January 13
January 9th 2020In October 2019, minocycline was the first topical foam to be approved by the FDA for any condition. The once-daily therapy will be available in retail, community, and specialty pharmacies, according to Foamix.
HIV Attacks Young Brain, Even with Early Treatment
January 8th 2020Recent studies have shown that the HIV virus may affect the brains of children living with and exposed to the virus, even with early antiretroviral therapy (ART). HIV can disrupt neurodevelopment, which affects how children learn, reason, and function.
Single Dose HPV Vaccine May Provide Similar Protection to Women as Multiple Doses
January 8th 2020One dose of the human papillomavirus (HPV) vaccine may prevent infection from the potential cancer-causing virus, according to research published in Jama Network Open, from the University of Texas Health Science Center at Houston.
Flu Activity High During Last Week of 2019, Continues to Rise
January 6th 2020The final weeks of 2019 saw high seasonal influenza activity across the United States, and the CDC said it continues to increase, according to the Weekly Influenza Surveillance Report for the week ending in December 28, 2019.
Enforcement Against Unauthorized Flavored E-Cigarettes Appealing to Children Prioritized by FDA
January 6th 2020Under this policy, companies that do not cease manufacture, distribution, and sale of unauthorized flavored cartridge-based e-cigarettes within 30 days risk enforcement actions by the federal agency.
Breastfeeding and Parity Linked to Lower Risk of Death by Accidents and Suicide
December 6th 2019Death by external causes—primarily accidents and suicide—take the lives of more than 5 million people each year, and it has evolved into a major health concern on a global scale. External causes also include violence, undetermined causes, and medical procedures.
New Universal Influenza Vaccine in Development
December 4th 2019In partnership with a team of medical centers, universities, and private industries, Emmes, a scientific research company, will support the development of a “universal influenza vaccine†that could provide longer-lasting protection than the current vaccines available, according to a company press release. The vaccine would also combat a wider variety of influenza viruses.